<DOC>
	<DOCNO>NCT00613613</DOCNO>
	<brief_summary>The purpose study learn whether genetics play role predict response commonly use FDA ( Food Drug Administration ) approve medication lower triglyceride cholesterol . Our hypothesis : The pharmacogenetics gene affect drug metabolism ( body handle drug ) drug target ( drug act body ) influence person responds lipid lower medication- fenofibrate .</brief_summary>
	<brief_title>Fenofibrate Pharmacogenetic Impact Dyslipidemia</brief_title>
	<detailed_description>We seek screen 200 subject select candidate gene serve source subject may participate genotype guide investigation predictability response base genotype . Response endpoint relate lipid parameter variables interest cardiovascular endpoint . Subjects genotypes interest would enrol short term clinical trial evaluate response fenofibrate base genetic profile ascertain screen phase . We hope evaluate ~50 subject second phase .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>1875 year old Be willing participate study attend schedule clinic exam Consent take lipid lower therapy 4 week necessary discontinue lipid lower agent period 8 week &lt; 18 year age History liver , kidney , pancreas , pancreatitis , gall bladder disease malabsorption ( Crohn 's disease etc . ) Use insulin currently take warfarin Pregnant woman woman childbearing potential use acceptable form contraception History allergy hypersensitivity fenofibrate Investigational drug use within 30 day study A disease , opinion , PI , would put subject risk study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>